Aesthetic Innovation Summit

April 25, 2018

Cytrellis Executive Summary

Company	**Clinical stage, aesthetic medical device company, technology developed out of MGH in Boston, MA**
Market Opportunity	**Addresses need in large self-pay aesthetic market for a more effective skin tightening treatment with less downtime**
Technology	***Proprietary micro-coring skin removal technology* is an entirely new category of dermatological treatment with versatility for many, high value opportunities**
Clinical Results	**More than 80 subjects treated to date, remarkable clinical results for *skin tightening*, unique in the market**
Financing	**Recently closed over subscribed Series B round of $28.5M, proceeds will complete clinical pivotal study, gain FDA clearance**

Experienced Leadership Team With Successful Track Record

Leadership

Karen Cronholm
President & CEO and Board Member

Patricia Krantz
VP Clinical/Regulatory

Diane Marcou
CFO

Strong Background in Product Development and Commercialization

- Successful clinical development and numerous regulatory clearances of aesthetic devices
- Leadership through multiple successful exits
- History of ground-breaking innovations in aesthetics

Board

Frederick Beddingfield, MD, PhD
CEO Sienna Bio

Keith Crandell
ARCH Venture Partners

Michael Peterson
CTO Merz Device Innovation Center

John McDonough
CEO T2 Biosystems

Amit Munshi (Chair)
CEO Arena Pharma

Diverse Collective Experience at Leading Aesthetic Companies

Allergan
KYTHERA BIOPHARMACEUTICALS
ZELTIQ Ahead of the curve.
ulthera
CYNOSURE
sienna biopharmaceuticals

Distinguished Founders and Advisors from Leading Institutions

Founders

Rox Anderson, MD

Director, Wellman Center for Photomedicine, MGH; Prof. Derm, HMS

- Conceived and pioneered several ground-breaking laser technique in aesthetics medicine
- Co-invented Zeltiq's Coolsculpting procedure
- Co-founded Seventh Sense Biosystems, Inc., Follica, Inc., Freedom-2, Inc
- Currently serves as a clinical / scientific advisor for several of aesthetic companies

William Austen, MD

Chief, Divisions of Plastic and Reconstructive Surgery and Burns Surgery, MGH

- Developed numerous patents and prototypes related to anti-aging, rejuvenation and scar therapy
- Published more than 75 peer-reviewed publications and has over 20 patents pending
- Currently serves as a professor of surgery at Harvard Medical School, where he also received his medical degree

Clinical Advisors

Mathew Avram, MD	**Roy Geronemus, MD**
Ashish Bhatia, MD	**Michael Kaminer, MD**
Brian Biesman, MD	**Suzanne Kilmer, MD**
Jay Burns, MD	**Jason Pozner, MD**
Jill Waibel, MD	**Val Lambros, MD**

- Top KOLs in the aesthetic industry
- Extensive experience founding and advising and commercializing successful aesthetic products
- Actively supporting Cytrellis' clinical program

Significant Unmet Needs Exist in the Aesthetic Market

Market Need for Improved Skin Tightening:

- **Current Treatments:** Plagued by limited efficacy, long downtime and retreatments[1]
- **Physicians:** Dissatisfied with current devices to treat skin laxity due to limited efficacy as well as inconsistency of results[1]
- **Patients:** Demanding dramatic skin tightening results, but do not want surgery[2]

% of women surveyed who would not consider surgery[3]



Physician satisfaction with current skin tightening treatments rated as a 3 on a 1 to 5 scale: [1]

5=Very Satisfied
4=Satisfied
3= Neither Satisfied nor Unsatisfied
2= Unsatisfied
1= Very Unsatisfied

[1]Cytrellis survey of 45 dermatologists and plastic surgeons (2015)
[2]ASAPS practitioner survey (2015)
[3] Cytrellis consumer survey of 1052 women in the US and Canada

Our Technology is an Entirely New Category of Skin Tightening



High Throughput Micro-excisions Promote Skin Tightening



Tightening along skin's natural tension lines, on average 9% reduction in width*

Micro-scale excisions

- Below size that causes scar
- Mechanical only, no use of energy

Physical hole closure

- Quantitative and directional reduction in area of skin
- Wrinkle improvement, tightening and smoothing of lax skin
- Skin rejuvenation

*Cytrellis clinical pre-auricular study conducted in 2014

OCT Images: Immediate Post Treatment – Cytrellis vs Laser



Post Cytrellis Treatment:
At 10 min, channels are closed, possibly cause of faster healing**



Post Ablative Laser Treatment:
At days 2 to 7, channels appear closed*

*Time related closure of AFXL-channels (25 mJ/microbeam) *"Spatiotemporal closure of fractional laser-ablated channels imaged by optical coherence tomography and reflectance confocal microscopy",* Banzhaf, CA, MD. et.al, Vol. 48, Issue 2, Dermatology and Plastic Surgery, 2/2016, pp 157-165
**OCT (Optical Coherence Tomography) images courtesy of Jill Waibel, MD 2018, captured using Vivosight technology (Michelson Diagnostics)

Clinical Results: Tightening and Wrinkle Improvement

Baseline

After Cytrellis Treatment*

*Patient treated with 5% skin removal, 90 days post multiple treatments
Courtesy of Roy Geronemus, MD

Clinical Results: Tightening and Lifting



Baseline

After Cytrellis Treatment*

*Patient treated with 5% skin removal, 90 days post multiple treatments
Courtesy of Jay Burns, MD

Clinical Results: Healing and Social Downtime Profile

- **Downtime expectations:**
  - 79% of women expect some level of downtime for an effective treatment with long lasting effects[1]
- **Cytrellis social downtime: Average 3 days**
  - 75% of subjects did not miss work
  - 46% of subjects did not miss any social/leisure activities
- **Average pain:** 0.36 (0-10 scale) during treatment and 0 for all subsequent timepoints
- **Healing profile (e.g. Erythema, swelling, etc.):** None to Trace levels at Day 3 and all subsequent timepoints

Cytrellis' treatment provides significant results and better downtime profile than existing devices

Healing Profiles

Baseline Day 3 Day 7

Baseline Day 7 Day 30

Subjects treated at 5% skin removal

[1] Cytrellis survey of 1052 women age 35+ in US and Canada

Histological Analysis: Baseline to 60- 90 days Post Treatment

- Increase in Collagen:Elastin ratio, indicating skin rejuvenation
- No scarring observed

Baseline



Day 60



Baseline



Day 90



Baseline



Day 90



Courtesy of Ashish Bhatia, MD & Karl Napekoski, MD

Device Overview: Patented Micro-Excision Technology

- **Micro-excisional concept is simple, but technology is sophisticated**
- **Highly differentiated product, strong IP position**
- **In-depth knowledge of mechanisms and software required to accurately and precisely remove micro-cores of skin**
- **Prototype developed and currently used in clinic:**
  - Includes a hand-held device and consumables
  - Capable of quickly treating large surface areas on the face
  - Fast, automated coring mechanism
  - Precise control of location, depth of micro-excisions
  - Clearance of cored tissue
- **Commercial device designed**



Conclusions

- Cytrellis' exciting novel micro-excisional device meets the market need for a more effective treatment for skin tightening with less downtime
- Excellent results can be achieved without the use of thermal energy
- New technique offers the ability to remove a significant amount of damaged, lax skin without concern of scarring or pigmentary change
- Recent fundraising activities will fund pivotal clinical studies, anticipating FDA clearance in 2019